SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

8304	Companies
115195	Keywords
55510	Articles
62563	Press releases

Home
Companies
SANOFI-AVENTIS

BRIEF

published on 09/16/2024 at 18:49, 2 months 5 days ago

Sanofi publie ses données sur les actions et les droits de vote pour août 2024

Actions Droit De Vote Relations Avec Les Investisseurs Sanofi Août 2024
BRIEF

published on 09/16/2024 at 18:49, 2 months 5 days ago

Sanofi Reports Share and Voting Rights Data for August 2024

Voting Rights Shares Investor Relations Sanofi August 2024
PRESS RELEASE

published on 09/16/2024 at 18:44, 2 months 5 days ago

Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2024
Annonce des droits de vote et d'actions de Sanofi conformément au Code de commerce et au Règlement de l'AMF

Droits De Vote Code De Commerce Actions AMF Sanofi
PRESS RELEASE

published on 09/16/2024 at 18:44, 2 months 5 days ago

Sanofi: Information concerning the total number of voting rights and shares - August 2024
Sanofi discloses total number of voting rights and shares as per French Commercial Code and AMF regulations

Voting Rights French Commercial Code Shares AMF Regulations Sanofi
BRIEF

published on 09/11/2024 at 07:10, 2 months 11 days ago

Dupixent Phase 3 Study Shows Promise for CSU Patients

Sanofi Phase 3 Dupixent CSU Regeneron
BRIEF

published on 09/11/2024 at 07:10, 2 months 11 days ago

L'étude de phase 3 sur Dupixent se révèle prometteuse pour les patients atteints de CSU

Sanofi Phase 3 Dupixent CSU Regeneron
BRIEF

published on 09/11/2024 at 07:05, 2 months 11 days ago

Dupixent démontre une efficacité significative dans le traitement du pemphigoïde bulleux

Essai Clinique Sanofi Dupixent Pemphigoïde Bulleuse Rémission De La Maladie
PRESS RELEASE

published on 09/11/2024 at 07:05, 2 months 11 days ago

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU. Positive pivotal data support Dupixent as a new targeted therapy for CSU

Phase 3 Study Dupixent CSU Chronic Spontaneous Urticaria Itch And Hives
BRIEF

published on 09/11/2024 at 07:05, 2 months 11 days ago

Dupixent Demonstrates Significant Efficacy in Bullous Pemphigoid

Clinical Trial Sanofi Dupixent Bullous Pemphigoid Disease Remission
PRESS RELEASE

published on 09/11/2024 at 07:05, 2 months 11 days ago

Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée
Dupixent : résultats positifs de l'étude de phase III confirmant l'efficacité du traitement de l'urticaire chronique spontanée non contrôlée. Nouvelle soumission réglementaire aux États-Unis

Traitement Dupixent Étude De Phase III Résultats Positifs Urticaire Chronique Spontanée

Accesswire

Published on 11/22/2024 at 09:00, 1 hour 7 minutes ago

Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Published on 11/22/2024 at 00:00, 10 hours 7 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 12 hours 2 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 12 hours 17 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 13 hours 52 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 09:45, 22 minutes ago

The GSMA – China Unicom Open Gateway Global Use Case Innovation Challenge has begun!
Published on 11/22/2024 at 09:23, 44 minutes ago

Turkiye Garanti Bankasi A.S.: Announcement regarding issuance of subordinated notes
Published on 11/22/2024 at 09:06, 1 hour 1 minute ago

Original-Research: NFON AG (von NuWays AG): Buy
Published on 11/22/2024 at 09:05, 1 hour 2 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 11/22/2024 at 09:03, 1 hour 4 minutes ago

Amundi Physical Metals plc: UK Final Terms

Les Echos

Published on 11/21/2024 at 06:58, 1 day 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 3 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 14 hours ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 14 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE